Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01168-5The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.
Nature Reviews Clinical Oncology, Published online: 15 June 2026; doi:10.1038/s41571-026-01178-3Teclistamab monotherapy improves survival in RRMM
dlvr.it
Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01164-9Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities.
Nature Reviews Clinical Oncology, Published online: 12 June 2026; doi:10.1038/s41571-026-01177-4Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia
Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01175-6Ivonescimab improves overall survival
Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01172-9Adjuvant selpercatinib shows benefit in patients with NSCLC
Nature Reviews Clinical Oncology, Published online: 10 June 2026; doi:10.1038/s41571-026-01161-yTraditional radiotherapy approaches involve the delivery of a uniform radiation dose to the entire tumour. Despite considerable effectiveness, this approach comes with the limitations of a lack of activity against larger tumour volumes as well as off-target irradiation of surrounding non-malignant tissues. Spatially fractionated radiotherapy, involving deliberate non-uniform irradiation, has the potential to address these challenges, with early data suggesting safety and activity in patients with advanced-stage cancers. In this Review, the authors describe the emerging role of spatially fractionated radiotherapy in the management of patients with cancer.
Nature Reviews Clinical Oncology, Published online: 10 June 2026; doi:10.1038/s41571-026-01160-zDespite considerable improvements in the outcomes in patients with hepatocellular carcinoma (HCC), many outstanding research questions remain unanswered. Furthermore, significant findings from successful phase III trials have not always been translated into guideline-recommended therapies, implying a need for improved standardization of trial end points. In this Consensus Statement, representatives of four major societies (the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO)) convened to provide guidance on end point selection for clinical trials conducted in various settings including surveillance, and early-stage, intermediate-stage and advanced-stage HCC.
